Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

Clinical trial NCT03696212 · TERMINATED

Trial details

NCT number: NCT03696212
Sponsor: Arrys Therapeutics
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Adenocarcinoma

Start date: 2019-01-08
Primary completion: 2021-02-15
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.